![双[三(羟甲基)氨基甲烷],CAS:6976-37-0](http://struc.chem960.com/strucimg/7000/ctzw0nzi34oyob9fnlmhiwee.png)
Detroit R＆D，Inc.成立于1997年，由Hyesook Kim博士创立，致力于提供最高质量的产品，专于研究环境健康科学，高血压和乳腺癌和前列腺癌领域，包括：生物活性类花生酸，环境雌激素，氧化应激，DNA损伤，非洲爪蟾，药物代谢，糖基化c-myc和p53，乳腺和前列腺微阵列和伤口愈合。
Detroit R&D公司由Dr. Hyesook Kim创立于1997年，Detroit R&D通过领先的技术提供优质产品，致力于赢得科研工作者的绝对信任。Detroit R&D的特色产品涉及环境健康科学、高血压、乳腺癌和前列腺癌相关研究领域，包括类花生酸生物活性研究相关产品，如EET,DHET和20-HETE；环境雌激素产品，如BPA，PGHS（也叫COX）；细胞色素P450（CYPs）;谷胱甘肽S-转移酶(GSTs);氧化应激；DNA损伤；非洲爪蟾蜍；药物代谢；乳腺和前列腺微阵列；创伤修复等相关产品。
• Research on biologically active eicosanoids such as EET, DHET, 20-HETE ａnd 8-isoprostane, environmental estrogens such as BPA, prostaglandin H synthase (PGHS, also called COX), cytochromes P450 (CYPs), glutathione S-transferases (GSTs), oxidative stress, DNA damage, Xenopus, drug-metabolism, glycosylated c-myc ａnd p53, breast ａnd prostate microarrays ａnd wound healing.
• Novel hypertension (US patents) ａnd breast cancer (patent pending) drug screening kits.
• Anti-breast cancer drug candidates (patent pending).
Detroit R&D has established a track record of success:
· Sales of products to Belgium, Japan, Germany, Australia, Italy, Hong Kong, Thailand, Czech Republic, China, USA, Canada, South Korea, United Kingdom, Brazil, Spain, Kuwait, ａnd Taiwan by direct sales ａnd via distributors.
· We have funding for 17 National Institutes of Health (NIH) SBIR Phase I ａnd II projects (>8.5 million), including hypertension diagnosis, mitochondrial DNA damage ａnd cancer microarray projects.
Pending grants: SBIR Phase II (PI, glycosylated proteins in breast cancer), R21 (PI, prostate cancer cachexia) ａnd Norway Prostate Cancer grant (Co-I, Glycosylated proteins in prostate cancer). > Detroit R&D holds 7 issued ａnd 6 pending patents.
代理商名称：上海远慕生物有限公司
供货：4周左右
Detroit R&D公司由Dr. Hyesook Kim创立于1997年，Detroit R&D通过领先的技术提供优质产品，致力于赢得科研工作者的绝对信任。Detroit R&D的特色产品涉及环境健康科学、高血压、乳腺癌和前列腺癌相关研究领域，包括类花生酸生物活性研究相关产品，如EET,DHET和20-HETE；环境雌激素产品，如BPA，PGHS（也叫COX）；细胞色素P450（CYPs）;谷胱甘肽S-转移酶(GSTs);氧化应激；DNA损伤；非洲爪蟾蜍；药物代谢；乳腺和前列腺微阵列；创伤修复等相关产品。
• Research on biologically active eicosanoids such as EET, DHET, 20-HETE ａnd 8-isoprostane, environmental estrogens such as BPA, prostaglandin H synthase (PGHS, also called COX), cytochromes P450 (CYPs), glutathione S-transferases (GSTs), oxidative stress, DNA damage, Xenopus, drug-metabolism, glycosylated c-myc ａnd p53, breast ａnd prostate microarrays ａnd wound healing.
• Novel hypertension (US patents) ａnd breast cancer (patent pending) drug screening kits.
• Anti-breast cancer drug candidates (patent pending).
Detroit R&D has established a track record of success:
· Sales of products to Belgium, Japan, Germany, Australia, Italy, Hong Kong, Thailand, Czech Republic, China, USA, Canada, South Korea, United Kingdom, Brazil, Spain, Kuwait, ａnd Taiwan by direct sales ａnd via distributors.
· We have funding for 17 National Institutes of Health (NIH) SBIR Phase I ａnd II projects (>8.5 million), including hypertension diagnosis, mitochondrial DNA damage ａnd cancer microarray projects.
Pending grants: SBIR Phase II (PI, glycosylated proteins in breast cancer), R21 (PI, prostate cancer cachexia) ａnd Norway Prostate Cancer grant (Co-I, Glycosylated proteins in prostate cancer). > Detroit R&D holds 7 issued ａnd 6 pending patents.
代理商名称：上海远慕生物有限公司
供货：4周左右
供货：4周左右
